

Identification And Molecular Characterization Of Non-Tuberculous Mycobacteria In Tuberculosis Suspected Patients.

Nadeem Gul Dar¹, Dr. Geeta Gupta², Dr. Sachin Kishore^{3*}, Dr. Nazia Khanum⁴, Dr. Shagufta shahi⁵, Dr. Zafar Nowshad Wani⁶, Shabir Ahmad Lone⁷

1PhD Scholar, Department of Microbiology, Santosh Medical College, Ghaziabad, Uttar Pradesh, India 201009.

2Professor, Department of Microbiology, Santosh Medical College, Ghaziabad, Uttar Pradesh, India 201009.

3Associate Professor, Department of Microbiology, Autonomous State Medical College, Mirzapur, Uttar Pradesh, India 231001.

4Microbiologist, Department of Microbiology, SVS Medical College Mahbubnagar, Telangana, India 509001.

5Microbiologist, IRL Srinagar, Jammu and Kashmir, India 190001.

6Department of Microbiology, Sher-i-Kashmir Institute of Medical Sciences, Srinagar Jammu and Kashmir, India 190001.

7Microbiologist, SKIMS, Sri Nagar, Jammu and Kashmir, India 190001.

Correspondence*: Dr Sachin Kishore,

E-mail address- sachinkishore@ymail.com

Cite this paper as: Nadeem Gul Dar, Dr. Geeta Gupta, Dr. Sachin Kishore, Dr. Nazia Khanum, Dr. Shagufta shahi, Dr. Zafar Nowshad Wani, Shabir Ahmad Lone (2024) Identification And Molecular Characterization Of Non-Tuberculous Mycobacteria In Tuberculosis Suspected Patients. *Frontiers in Health Informatics*, 13 (4), 88-98

ABSTRACT

Introduction: The study aims to identify and characterize nontuberculous mycobacteria at the molecular level in patients suspected of having tuberculosis, as standardized identification criteria are recommended by the American Thoracic Society for quicker clinical and laboratory procedures.

Method: 772 samples were collected from 386 patients (2 each) in selected districts of Jammu and Kashmir. In addition to phenotypic, molecular methods were also used to detect the number and species of Non tuberculous mycobacteria. Records of patients were collected for clinical information, such as symptoms and radiological findings. **Results:** Out of 772 samples, 180 (23.31%) were positive for acid-fast bacteria, with 164 (91.11%) and 16 (8.89%) identified as *M. tuberculosis* complex and NTM strains. *Mycobacterium abscessus* and *M. intracellulare* isolates were the most frequent. Common symptoms included cough, fever, shortness of breath, weight loss, sputum production, appetite loss, night sweating, and thrombocytosis. **Conclusion:** A study of 386 patients revealed that most were over 40 years old, with a higher rate of non-tuberculous mycobacteria (NTM) infections in males. Common symptoms included cough, fever, shortness of breath, weight loss, and sputum production. Positive cultures showed 91.11% MTB complexes and 8.89% NTM growth. The study identified 5 different mycobacterial species with 100% concordance.

INTRODUCTION

Tuberculosis, an ancient disease, has been present in humans since prehistory. It may have first appeared around 150 million years ago[1]. Despite the first humans leaving Africa 1.7 million years ago[2], they likely brought TB with them. Written accounts date back as long as 2300 years in China and 3300 years in India[3,4].

Mycobacterium tuberculosis was once the only *Mycobacterium* infection in humans, causing significant social impact. Other mycobacterium species, known as anonymous or atypical mycobacteria, mycobacteria other than tuberculosis (MOTT), and non-tuberculous mycobacteria (NTM), are more common and have thicker, lipid-rich cell walls. Mycobacteria, resistant to hydrophilic nutrients, heavy metals, antibiotics, and disinfectants, are found in various environments. Non-tuberculous mycobacteria (NTM) spread disease at varying rates, and host factors are now considered more significant in the pathophysiology of NTM infections, despite environmental variables being suspected. Host-organism interaction can occur due to environmental exposure or host components[5,6]. Soil and water sources have high concentrations of NTM, which contributes to biofilm growth and antibiotic resistance. NTM's hydrophobicity allows preferential aerosolization from water, and many species can withstand high temperatures and low pH[7,8].

There is limited evidence that NTM is spread from human to human, unlike leprosy and tuberculosis. Since NTM infections cannot widely spread, they are not reported; yet, there are few surveillance data available. It has been demonstrated that over 140 distinct mycobacteria species are hazardous to humans. Among NTM species that cause sickness in humans, *Mycobacterium avium* complex (MAC) and *Mycobacterium kansasii* are the most common[9,10].

From the early 20th century, reports of non-tuberculous mycobacteria from clinical specimens were infrequent. However, in the 1950s, a new concept emerged, focusing on mycobacterial infection and the relationship between infection with organisms other than the tubercle bacillus and mild tuberculin responses. Two "novel" mycobacterial infections were described, establishing mycobacteria other than tuberculous bacilli as serious human illnesses. NTM infections are not reportable in India, making it difficult to determine prevalence due to clinical, radiographic, and microbiological criteria. Factors such as immune-suppressive medications, immune deficiency disorders, and chronic structural lung illnesses contribute to the increase in NTM infections[11,12].

NTM infection can manifest in various areas, including the lung, skin, soft tissues, lymphadenitis, empyema, eye, central nervous system, and genitourinary infections. Initially believed to be untransferable, genetic evidence suggests human-to-human transmission[13]. Treatment typically involves antibiotics, with surgery for non-responsive patients, posing a high risk of complications[14].

Non-tuberculous mycobacterial pulmonary disease (NTM-PD) is a common comorbidity in patients with underlying respiratory diseases like bronchiectasis, cystic fibrosis, and chronic obstructive pulmonary disease[15]. Common NTM species causing NTM-PD include *Mycobacterium avium* complex, *Mycobacterium kansasii*, *Mycobacterium xenopi*, *Mycobacterium abscessus*, and *Mycobacterium malmoense*[16]. The discussion of pulmonary NTM disease in relation to tuberculosis is motivated by two factors: NTM-related lung illness shares symptoms with TB, and NTM isolates may become resistant to first-line anti-TB drugs[17].

Unfortunately, it can be challenging to diagnose NTM infections, and patients commonly receive a delayed or inaccurate diagnosis, which can have detrimental long-term effects. The purpose of this research was to identify and characterize non-tuberculous mycobacteria at the molecular level in people who may have tuberculosis.

MATERIAL AND METHODS

A study analyzed 772 clinical samples of 386 patients suspected of having tuberculosis between June 2021 and August 2024 in Jammu and Kashmir. The majority were male. Standardization from ATS/IDSA and American Thoracic Society was used to identify NTM isolates[18]. Patients with at least two positive cultures were included.

NTM identification using phenotypic and genotypic testing

The study involved decontaminating sputum specimens with N-acetyl-L-cysteine, staining them with Ziehl-Neelsen, and preparing them for Acid Fast Bacilli (AFB) smear microscopy. Cultured in Lowenstein-Jensen medium[19], they were incubated for eight weeks[20]. To differentiate between MTB and NTM[21], SD Bioline TB Ag was used to expose AFB-positive growth to the MPT64 antigen. PCR and biochemical testing were used to identify the species, all based on Centers for Disease Control (CDC) procedures for the isolation of NTM strains.

Immunochromatographic assay (ICA):

The SD Bio-Line MPT64 TB test was used for rapid immunochromatographic assay (ICA) to differentiate between MTB and NTM[21]. 200 µL of extraction buffer was used to emulsify three or four colonies of mycobacterial strains culture, adding 100 µL to each well, and visually assessing the results using color development after 15 minutes of incubation.

Molecular methods of identification

Extraction of DNA by boiling

A colony of bacteria was aseptically extracted and subsequently placed in an eppendorf tube containing 100 µl of sterile water. The sample was subjected to vortexing for a duration of 10 to 15 seconds. Following this, the tube was heated to 99°C for five minutes utilizing a Biometra T 3000 thermal cycler. After centrifugation at 12,000 rpm for 10 minutes, the supernatant was carefully removed and stored at 4°C. To determine the concentration of DNA, a NanoDrop™ spectrophotometer (Thermo Scientific) was employed to evaluate the concentration and purity of the final DNA extract obtained from the bacterial culture. The NanoDrop was calibrated according to the manufacturer's instructions. Once the system was operational, the sensor was cleaned with 1 µl of sterile water. After performing a second blanking, 1 µl of the DNA sample was applied to the sensor, and the results were

recorded.

PCR Preparation for all NTM isolates:

Several targets were amplified from the mycobacterial DNA using PCR. All reactions shared the same basic reaction mix composition, with the following little adjustments needed for different targets. Every amplification was done in a 50µl final reaction volume. The master mix concentration for each target is displayed in Table 1.

Table 1. Throughout this investigation, Bioline™ products (core kit) were utilized.

Table 1: Master Mix volumes for target								
Target	10X Buffer	25mM MgCl ₂	100mM dNTP	Primer mix F/R	Taq Polymerase	DNA Template	H ₂ O	Total
Hsp65	5 µl	3 µl	1 µl	1 µl	0.5 µl	3 µl	35.5 µl	50 µl

Primer Sets for identification of NTMs

Amplifying region	5'	3'
Hsp65 (TB11/12)	TB11-ACCAACGATGGTGTGTCCAT	
	TB12-CTTGTCGAACCGCATACCCT	

Molecular Diagnosis of NTM

NTM strains were analyzed using restriction enzyme techniques and polymerase chain reaction for species identification. The hsp65 protein is universally present in all mycobacterial species, with both common and unique epitopes. Standard primers including Tb11 (5' – CAACGATG GTGTGTCCCAT) and Tb12 (5' – CTTGTCTGAACCGCAT ACCCT) were used for amplification, and distinctiveness enabled differentiation into specific species or subspecies. Agarose gel electrophoresis separated digestion products, revealed patterns associated with individual species.

Restriction enzyme analysis

The 10 µl of PCR product was digested with BstE II and HaeIII enzymes, respectively, in a solution containing 0.5 U of enzyme, 2.5 U of restriction buffer, and 11.5 µl of water. The mixture was incubated at 60°C for 60 minutes, and at 37°C for the same process. The digested products were loaded on 3% agarose gel electrophoresis at 100 V for 2 hour. To interpret the restriction analysis profiles obtained by different species, 50 bp ladder DNA size marker was used. The fragments were detected with ethidium bromide staining and UV transilluminator.

Table 3: Age group wise distribution of suspected cases of pulmonary tuberculosis		
Age groups	No. of cases	Percentage
19-29	178	46.11
30-40	116	30.05
>40	92	23.84
Total	386	100

RESULTS


The study collected

demographic data from 386 patients, categorized into three age groups based on ten-year intervals. The highest age group was those over 40 years, with 178 cases. The 30-40year age group had 116 cases, and the 19-29year age group had 92 cases.

The study revealed a higher prevalence of NTM infections among males, with 204 males and 182 females identified out of 386 patients.

Table 2: Gender wise distribution of suspected cases of pulmonary tuberculosis		
Gender	No. of cases	Percentage
Male	204	52.85
Female	182	47.15
Total	386	100



Mycobacterium infection symptoms include cough, fever, shortness of breath, weight loss, sputum production, appetite loss, night sweat, Thoracic pain, and hemoptysis.



The study involved collecting 772 sputum samples using a modified Petroff's method. After decontamination, the samples were inoculated onto Lowenstein-Jensen medium slants and incubated at 37°C for up to four weeks. 124 samples tested positive for ZN staining, and 180 samples contained positive mycobacteria. The MPT 64 antigen-based immunological test was used to analyze the presence of MTB complexes or non-tuberculous mycobacteria (NTM) growth. Biochemical tests, including niacin, nitrate, and heat-resistant catalase, confirmed the positive growth findings. The results showed that 16.65% of the samples were NTM growth, while 95.34% were identified as *M. tuberculosis* complexes.

Table 5: Identification of Mycobacterium species by various methods

Test method	Test Positive
Direct ZN staining	124/772 (62 out of 386 patients)
Culture on LJ media	180/772 (90 out of 386 patients)
MPT64 antigen	162/180 (81 out of 90 patients)
MTB Complex	164/180 (82 out of 90 patients)
NTM	16/180 (8 out of 90 patients)



Lung fibrosis, observed in 88.86% of cases, is the most prevalent clinical manifestation, followed by cervical lymphadenopathy at 68.65%, nodularity at 61.40%, and unilateral lung involvement at 60.88%.


Figure: X-ray findings of lung with suspected TB infections

Figure: DNA amplification band






Figure: Restricted enzyme analysis



The PCR-REA method used to identify mycobacteria, revealed five distinct species. The study identified all eight strains of Mycobacteria at the species level when digested with BstE11 and Hae111 restriction enzymes. The most frequently encountered species was Mycobacterium abscessus. The PCR-REA test showed a strong correlation with biochemical identification, achieving a 100% concordance rate. The identified species were *M. chelonae* (12.5%), *M. abscessus* (37.5%), *M. intracellulare* (25%), *M. fortuitum* (12.5%), and *M. kansasii* (12.5%). 50% of samples contained isolates classified as rapidly growing mycobacteria, specifically *M. abscessus* and *M. chelonae*.



DISCUSSION

NTM's status as a major human pathogen has been cemented by a noteworthy increase in both individual cases and outbreaks over the past ten years. Previously, mycobacteria were distinguished at the species level through biochemical tests, a process that usually takes three to six weeks [22,23], this study investigates the use of various molecular techniques to quickly distinguish NTM isolates from two hospitals in southern Ireland at the species and sub-species levels. Previously, isolates of mycobacteria (NTMs) were identified as separate species in hospital labs. NTMs, found in various environments, can cause various clinical symptoms. Diagnosing NTM pulmonary illness is challenging due to their similarity to tuberculosis. More precise diagnostic methods are needed, as smear microscopy cannot differentiate between MTBC and NTM infections. Special techniques are needed for treating MTBC and NTM effectively. However, because finding the organism does not necessarily indicate a clinical illness, it is challenging to determine the frequency and prevalence of NTM lung infections with accuracy. In the current study, 8 NTMs (2.07%) were found among 386 Pulmonary TB suspected patients (8 out of 90 culture positive patients, 8.88%). In a study conducted in Delhi, Jain et al. found that 13 NTMs were found in 237 lung samples, or 5.48% of the total. Nine of the thirteen NTMs in total were taken from extra pulmonary samples, whereas the other four were taken from pulmonary samples [24]. This investigation's findings aligned with the current study's findings. NTM levels in soil and water samples from Sewagram, Wardha, and those in patient clinical specimens were found to be related in 2007 by R. Narang et al. [25]. Twenty of the 26 NTM isolates that were found were isolated from soil, while six were isolated from water samples. Mycobacterium avium was the only species found in both environmental and clinical samples out of seven distinct NTM species. The majority of the individuals who took part in our research were men. Several studies conducted in India and other nations have shown that men were more susceptible to environmental NTM isolates due to their exposure in the workplace. In a study by M.V. Jesudason et al, [26], it was found that 64 cases (56%) involved males, while 51 cases (44%) involved females. K. G De Mello [27] from Brazil and Alejandro Hernandez-Solis from Mexico [28] represented 62.1%.

In this research, 9 isolates did not show positive results in the SD Bioline Ag MPT64 test, but 8 isolates tested negative using CBNAAT, indicating the presence of NTM. Based on Arora et al's findings, the SD Bioline Ag MPT-64 test may yield false negative outcomes due to a point mutation in the MPT64 gene. Therefore, for definitive confirmation of the presence of NTM, further molecular testing is necessary [29], which in our study was carried out using CBNAAT. Our research results indicate that the MPT 64 TB Ag rapid Immunochromatographic test has a sensitivity of 88.89%. The research conducted by S. Shenai [30], E. Streit [31], B. Varghese [32], and D. P. O'Brien [33] highlighted that NTM had a greater impact on the respiratory system compared to extra pulmonary infections.

Based on our investigation, Mycobacterium abscessus 3/8 (37.5%) appears to be the most prevalent NTM type,

followed by *Mycobacterium Intracellular* 2/8 (25%). These results align with and deviate from various studies conducted in India. A study by Prabha Desikan et al. [34] in Bhopal reported *M. abscessus* as the most frequently identified species at 53.8%, while research by Paramasivan et al. [35] in Chennai, South India, identified NTM in pulmonary samples of patients within the BCG clinical trial area, with *M. avium/intracellulare* being the most commonly isolated species at 22.6%. A study by B Nasr-Esfahani and colleagues [36] involved the amplification of a 441 base pair segment of the *hsp65* gene of NTM. This was followed by restriction digestion using *Bst*EI and *Hae*III endonucleases, and subsequent analysis of the restriction fragment patterns, leading to the identification of 19 (86.4%) NTM isolates. Three species showed profiles that differed from the known profiles of RFLP, making it impossible to ascertain. Turenne and Tschetter's research [37] demonstrated that *hsp 65* PRA was the most effective method for identifying certain NTM strains, such as *M. gastri* and *M. kansasii*, which could not be detected using alternative techniques. Wong and Yip's study [38] revealed that the *hsp65* gene PCR-RFLP can identify approximately 74.5% of NTM isolates. Telenti and Marchesi [39] utilized PCR-RFLP to categorize ten non-tuberculous mycobacteria (NTM) isolates to the species level. They amplified a 439 bp segment and subjected it to digestion using *Bst*EI and *Hae*III restriction enzymes. Our research revealed that *M. abscessus* accounted for 37.5% of NTM, *M. intracellulare* for 25%, *M. chelonae* for 12.5%, *M. fortuitum* for 12.5%, and *M. kansasii* for 12.5%. We observed that *M. abscessus* was the most frequently identified NTM in respiratory samples. V.P. Myneedu et al [40] documented a high prevalence of *M. simiae* isolates in patients with pulmonary and extrapulmonary diseases in New Delhi. In pulmonary samples, *M. fortuitum* was detected in 12.88% and ranked as the third most common NTM, while *M. chelonae* was present in 10.88% and ranked fourth. MV Jesudasan from Vellore identified *M. chelonae* as the most prevalent isolate at 8.1%, followed by *M. fortuitum*, accounting for 67% of NTM isolated from pulmonary samples. In the research conducted by Chakrabarthy et al., B Goswami et al., and Das et al. [41, 42], *M. fortuitum* was found to be the most common isolate. Analysis of molecular sequences from conserved genes like 16S rRNA, *hsp65*, *rpoB*, and the 16S-23S internal transcribed spacer region has resulted in faster diagnoses. To validate RFLP findings, sequence analysis was performed targeting the amplified *hsp65* gene product of NTM strains. Eight strains were confirmed as NTM species: *Mycobacterium abscessus* (3), *M. Intracellular* (2), *M. chelonae* (1), *M. fortuitum* (1), and *M. kansasii* (1). After analyzing 436 suspected isolates for NTM, Delhi-based Sarika Jain [42] and colleagues found 68 NTM isolates of 16 different species, 17 *Mycobacterium tuberculosis* complex isolates, and 3 each of *Rhodococcus equi*, *Tsukamurella pulmonis*, *Paenibacillus* spp., and *Nocardia carnea* isolates. Like Grace and colleagues from Zambia, their study's results demonstrate that all potentially dangerous strains can be found using DNA sequence analysis of the ITS region, with *M. intracellulare* being the most prevalent isolate (27.8%). In contrast, InesJoao et al. partially sequenced the *hsp65* and 16S rRNA genes of 54 clinical isolates and 22 reference strains. 16S rRNA sequencing alone is insufficient to reliably identify NTM species. To identify NTM at the species level, it is recommended to combine 16S rRNA gene and *hsp65* gene sequence analysis with various databases. Compared to 16S rRNA, *hsp65* performed better when a single gene was employed [43].

CONCLUSION

A study involving 386 patients found that the majority were over 40 years old, with a higher rate of non-tuberculous mycobacteria (NTM) infections observed in males. Common symptoms of mycobacterium infection included cough, fever, shortness of breath, weight loss, sputum production, loss of appetite, night sweats, thoracic pain, and hemoptysis. Sputum samples were collected and processed for culture, with negative cultures confirmed by smear examination. Positive cultures were further evaluated for mycobacterial growth using immunochromatography and biochemical tests. The results showed that 91.11% of positive cultures were MTB complexes, while 8.89% were identified as NTM growth. It was found molecular methods are accurate to differentiate species comparing with phenotypic methods and also biochemical tests are time consuming. A molecular diagnosis of NTMs identified *M. abscessus* as the most common species at 37.5%. All eight mycobacterial strains were analyzed for species identification using Polymerase chain reaction – restriction enzyme analysis, revealing that all mycobacteria possess a *hsp65* protein with unique and common epitopes. The PCR-REA method successfully identified 05 different types of mycobacterial species, with 100% concordance in species identification.

Funding:

No specific grant was obtained for this research from governmental, private, or nonprofit funding organizations.

Ethics statement

This study was approved by the Institutional Ethics Committee, Santosh Medical College Ghaziabad, UP, India (Letter No: SU/2019/1531[5])

AUTHOR CONTRIBUTIONS:

Nadeem Gul Dar and Geeta Gupta conceived the idea of the manuscript. Nadeem Gul Dar wrote the first draft of the manuscript. Nadeem Gul Dar, Nazia Khanum, Sachin Kishore commented and edited subsequent versions of the manuscript. All co-authors participated in data collection and analysis. All authors have reviewed and approved the final version of the manuscript submitted to the journal.

Conflict of interest:

The authors declare that there is no conflict of interest.

REFERENCES

- Daniel T M. History of tuberculosis. *Respiratory Med* 2006;100:1862-1870.
- Zimmerman MR. Pulmonary and osseous tuberculosis in an Egyptian mummy. *Bull NY Acad Med* 1979;55:604–8
- Morse D, Brothwell DR, Ucko PJ. Tuberculosis in ancient Egypt. *Am Rev Respir Dis* 1964;90:5224–541.
- Immerman MR. Pulmonary and osseous tuberculosis in an Egyptian mummy. *Bull NY Acad Med* 1979;55:604–8.
- Nerlich AG, Haas CJ, Zink A, Szeimies U, Hagedorn HG. Molecular evidence for tuberculosis in an ancient Egyptian mummy. *Lancet* 1997;350:1404.
- Crube'zy E', Ludes B, Poveda J-D, Clayton J, Crouau-Roy B, Montagnon D. Identification of *Mycobacterium* DNA in an Egyptian Pott's disease of 5400 years old. *C R Acad Sci Paris (Sciences de la vie)* 1998;321:941–51.
- Daniel VS, Daniel TM. Old testament biblical references to tuberculosis. *Clin Infect Dis* 1999;29:1557–8.
- Daniel TM. The early history of tuberculosis in central East Africa: insights from the clinical records of the first twenty years of Mengo Hospital and review of the relevant literature. *Int J Tuberc Lung Dis* 1998;2:1–7.
- Gibbons A. Modern men trace ancestry to African migrants. *Science* 2001;292:1051–2.
- Brown L. The story of clinical pulmonary tuberculosis. Baltimore, MD: Williams & Wilkins Company; 1941. 198
- Winthrop KL. Pulmonary Disease Due to Nontuberculous mycobacteria: an Epidemiologist's View. *Future Microbiology*. 2010 Mar 8;5(3):343–5.
- Stout JE, Koh WJ, Yew WW. Update on pulmonary disease due to non-tuberculous mycobacteria. *International Journal of Infectious Diseases*. 2016 Apr;45:123–34.
- Bryant JM, Grogono DM, Rodriguez-Rincon D, Everall I, Brown KP, Moreno P, et al. Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium. *Science* [Internet]. 2016 Nov 11 [cited 2020 Apr 20];354(6313):751–7. Available from: <https://science.sciencemag.org/content/sci/354/6313/751.full.pdf>
- Hyung Koo Kang, Hye Yun Park, Kim D, Jeong BH, Jeon K, Jong Ho Cho, et al. Treatment outcomes of adjuvant resectional surgery for nontuberculous mycobacterial lung disease. *BMC Infectious Diseases*. 2015 Feb 19;15(1).
- The Voice of the Patient Non-Tuberculous Mycobacterial (NTM) Lung Infection [Internet]. 2016 Apr. Available from: <https://www.fda.gov/media/96932/download>
- Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases. *American Journal of Respiratory and Critical Care Medicine*. 2007 Feb 15;175(4):367–416.
- Payam Tabarsi, Parvaneh Baghaei, Parissa Farnia, Mansouri N, Ehsan Chitsaz, Fatemeh Sheikholeslam, et al. Nontuberculous Mycobacteria Among Patients Who are Suspected for Multidrug-Resistant Tuberculosis—Need for Earlier Identification of Nontuberculosis Mycobacteria. *The American Journal of the Medical Sciences*. 2009 Mar 1;337(3):182–4.
- Aksamit T, Brown-Elliott B, Catanzaro A, Daley C, Gordin F, Holland S, Horsburgh R, Huitt G, Iademarco M, Iseman M (2007) ATS Mycobacterial diseases subcommittee american thoracic society, infectious disease society of america an ofcial ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. *Am J Respir Crit Care Med* 175(4):367416.
- Kent PT. (1985). Public health mycobacteriology: a guide for the level III laboratory: US Department of Health and Human Services, Public Health Service, Centers.
- Mackie & McCartney, J.G Collie, A.G.Fraser, B.P. Marmion, A.Simmons. *Practical Medical Microbiology*. Eighth

edition. Page: *Mycobacterium tuberculosis* bacilli. Page: 412.

Ribon W. Biochemical Isolation and Identification of *Mycobacteria*. In Jimenez-Lopez JC. (editor) *Biochemical Testing*: InTech 2012. doi: 10.5772/34309.

Gurpreet S. Bhallaa, Manbeer S. Saraob , Dinesh Kalrac , Kuntal Bandyopadhyayd , Arun Ravi Johnne. Methods of phenotypic identification of non-tuberculous mycobacteria. *Practical Laboratory Medicine* 12 (2018) e00107.

Nasstasja Wassilew, Harald Hoffmann, Claire Andrejak, Christoph Lange. Pulmonary Disease Caused by Non-Tuberculous *Mycobacteria*. *Respiration* 2016;91:386–402.

Ben Salah I1 , Cayrou C, Raoult D, Drancourt M. *Mycobacterium marseillense* sp. nov., *Mycobacterium timonense* sp. nov. and *Mycobacterium bouchodurhonense* sp. nov., members of the *Mycobacterium avium* complex. *Int J Syst Evol Microbiol.* 2009 Nov;59(Pt 11):2803-8.

Veronique Levy-Frebault, et al., *Mycobacterium fallax* sp. nov. *International Journal Of Systematic Bacteriology*, Apr. 1983, p. 336-343.

R Narang, P Narang, DK Mendiratta. Isolation And Identification Of Nontuberculous *Mycobacteria* From Water And Soil In Central India. *Indian Journal of Medical Microbiology*, (2009) 27(3): 247-50

MV Jesudason, P Gladstone. Non tuberculous mycobacteria isolated from clinical specimens at a tertiary care hospital in South India. Year 2005, Vol. 23, issue:3, Page: 172 – 175.

De Mello. Et al. 2013). Clinical and therapeutic features of pulmonary nontuberculous mycobacterial disease, Brazil, 1993-2011. *Emerging infectious diseases*, 19(3), 393–399

Alejandro Hernandez-Solis, et al. Nontuberculous mycobacteria in clinical samples with negative acid-fast. Year : 2017; Volume : 6; Issue : 4; Page : 391- 395

Arora J, Kumar G, Verma AK, Bhalla M, Sarin R, Myneedu VP. Utility of MPT64 antigen detection for rapid confirmation of *Mycobacterium tuberculosis* complex. *J Glob Infect Dis.* 2015;7:66–69.

S. Shenai, C. Rodrigues, and A. Mehta, “Time to identify and define nontuberculous mycobacteria in a tuberculosis-endemic region,” *The International Journal of Tuberculosis and Lung Disease*, vol. 14, no. 8, pp. 1001–1008, 2010

E. Streit, J. Millet, and N. Rastogi, “Nontuberculous *Mycobacteria* in Guadeloupe, Martinique, and French Guiana from 1994 to 2012,” *Tuberculosis Research and Treatment*, vol. 2013, pp. 1–8, 2.

B. Varghese, Z. Memish, N. Abuljadayel, R. Al-Hakeem, F. Alrabiah, and S. A. Al-Hajoj, “Emergence of clinically relevant non-tuberculous mycobacterial infections in Saudi Arabia,” *PLOS Neglected Tropical Diseases*, vol. 7, no. 5, Article ID e2234, 2013.

Kanade S1 , Nataraj G, Suryawanshi R, Mehta P. Utility of MPT 64 antigen detection assay for rapid characterization of mycobacteria in a resource constrained setting. *Indian J Tuberc.* 2012 Apr;59(2):92-6

Desikan, P., Tiwari, K., Panwalkar, N., Khaliq, S., Chourey, M., Varathe, R., ... Pandey, M. (2017). Public health relevance of non-tuberculous mycobacteria among AFB positive sputa. *Germs*, 7(1), 10–18. doi:10.18683/germs.2017.1103

Paramasivan C.N., Govindan D., Prabhakar R., Somasundaram P.R., Subbammal S and Tripathy S: Species level identification of non-tuberculous mycobacteria from south Indian BCG trial area during 1981. *Tubercle*; 1985; 66: 9.

B Nasr-Esfahani, *E Sarikhani, S Moghim, J Faghri, H Fazeli, N Hoseini, H Rezaei-Yazdi. Molecular Characterization of Environmental NonTuberculous *Mycobacteria* Using PCR- RFLP Analysis of 441 Bp Heat Shock Protein 65 Fragments. *Iranian J Publ Health*, Vol. 41, No.4, Apr 2012, pp.108- 114.

Turenne TC, Tschetter L, Wolfe J, Kabani A (2001). Necessity of quality controlled 16S rRNA gene sequence databases identifying nontuberculous mycobacterium species. *J Clin Microbiol*, 39: 3637–3648

Wong DA, Yip PC, Tse DL, Tung VW, Cheung DT, Kam KM (2003). Routine use of a simple low-cost genotypic assay for the identification of mycobacteria in a high throughput laboratory. *Diagn Microbiol Infect Dis*, 47: 421-426.

V.P. Myneedu, A.K. Verma, M. Bhalla, J. Arora, S. Reza, G.C. Sah and D. Behera. Occurrence Of Non-Tuberculous *Mycobacterium* In Clinical Samples - A Potential Pathogen. *Indian Journal of Tuberculosis*. 2013; 60: 71 – 76.

Chakrabarti A1 , Sharma M, Dubey ML. Isolation rates of different mycobacterial species from Chandigarh (north India). *Indian J Med Res.* 1990 Mar;91:111-4.

Das, S., Pettersson. Et al., (2016). The *Mycobacterium phlei* Genome: Expectations and Surprises. *Genome biology and evolution*, 8(4), 975– 985.

Joao I1 , Cristovao P2 , Antunes L3 , Nunes B4 , Jordao L5 . Identification of nontuberculous mycobacteria by partial gene sequencing and public databases. *Int J Mycobacteriol.* 2014 Jun;3(2):144-51.